<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2026/ffd-2026.xsd"
      xlink:type="simple"/>
    <context id="rc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
        </entity>
        <period>
            <startDate>2026-11-06</startDate>
            <endDate>2026-11-06</endDate>
        </period>
    </context>
    <context id="offrl_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-11-06</startDate>
            <endDate>2026-11-06</endDate>
        </period>
    </context>
    <context id="prosp_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:CmbndPrspctsItemAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-11-06</startDate>
            <endDate>2026-11-06</endDate>
        </period>
    </context>
    <context id="prosp_2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002023016</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:CmbndPrspctsItemAxis">
                    <dei:lineNo>2</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-11-06</startDate>
            <endDate>2026-11-06</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <ffd:FormTp contextRef="rc" id="ixv-368">S-3</ffd:FormTp>
    <ffd:SubmissnTp contextRef="rc" id="ixv-369">S-3</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="rc" id="ixv-370">EX-FILING FEES</ffd:FeeExhibitTp>
    <dei:EntityCentralIndexKey contextRef="rc" id="ixv-371">0002023016</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-372">Turn Therapeutics Inc.</dei:EntityRegistrantName>
    <ffd:OfferingTableNa contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa
      contextRef="rc"
      id="hiddenrcCombinedProspectusTableNa"
      xsi:nil="true"/>
    <ffd:Rule429CmbndPrspctsFlg contextRef="prosp_1" id="ixv-376">true</ffd:Rule429CmbndPrspctsFlg>
    <ffd:Rule429CmbndPrspctsFlg contextRef="prosp_2" id="ixv-377">true</ffd:Rule429CmbndPrspctsFlg>
    <ffd:FormTp contextRef="rc" id="ixv-420">S-3</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-421">Turn Therapeutics Inc.</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg contextRef="offrl_1" id="ixv-422">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="offrl_1" id="ixv-423">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_1" id="ixv-424">Common Stock, par value $0.0001 per share</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="offrl_1" id="ixv-425">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="offrl_1"
      decimals="0"
      id="ixv-426"
      unitRef="Shares">873000</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="offrl_1"
      decimals="2"
      id="ixv-427"
      unitRef="USD">9.90</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="offrl_1"
      decimals="2"
      id="ixv-428"
      unitRef="USD">8642700.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="offrl_1"
      decimals="6"
      id="ixv-429"
      unitRef="pure">0.000087</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="offrl_1"
      decimals="2"
      id="ixv-430"
      unitRef="USD">751.91</ffd:FeeAmt>
    <ffd:TtlOfferingAmt contextRef="rc" decimals="2" id="ixv-431" unitRef="USD">8642700.00</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="rc" decimals="2" id="ixv-432" unitRef="USD">751.91</ffd:TtlFeeAmt>
    <ffd:TtlPrevslyPdAmt contextRef="rc" decimals="2" id="ixv-433" unitRef="USD">0.00</ffd:TtlPrevslyPdAmt>
    <ffd:TtlOffsetAmt contextRef="rc" decimals="2" id="ixv-434" unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="rc" decimals="2" id="ixv-435" unitRef="USD">751.91</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="offrl_1" id="ixv-436">Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement (the "Registration Statement") covers an undetermined number of additional securities of Turn Therapeutics Inc. (the "Company") that may become issuable to prevent dilution from stock splits, stock dividends or similar transactions.

Consists of an aggregate of 873,000 shares of common stock, par value $0.0001 per share (the "common stock"), which were not included on the Prior Registration Statements (defined below).

Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) under the Securities Act based on the average of the high and low reported trading prices of the Company's common stock as reported on the Nasdaq Global Market on November 3, 2026, such date being within five business days of the date that this Registration Statement was filed with the U.S. Securities and Exchange Commission (the "SEC").</ffd:OfferingNote>
    <ffd:Rule429SctyTp contextRef="prosp_1" id="ixv-437">Equity</ffd:Rule429SctyTp>
    <ffd:Rule429SctyTitl contextRef="prosp_1" id="ixv-438">Common Stock, par value $0.0001 per share</ffd:Rule429SctyTitl>
    <ffd:Rule429NbOfUnsoldScties
      contextRef="prosp_1"
      decimals="0"
      id="ixv-439"
      unitRef="Shares">17868760</ffd:Rule429NbOfUnsoldScties>
    <ffd:Rule429AggtOfferingAmt
      contextRef="prosp_1"
      decimals="2"
      id="ixv-440"
      unitRef="USD">0.00</ffd:Rule429AggtOfferingAmt>
    <ffd:Rule429EarlierFormTp contextRef="prosp_1" id="ixv-441">S-1</ffd:Rule429EarlierFormTp>
    <ffd:Rule429EarlierFileNb contextRef="prosp_1" id="ixv-442">333-289972</ffd:Rule429EarlierFileNb>
    <ffd:Rule429InitlFctvDt contextRef="prosp_1" id="ixv-443">2025-09-30</ffd:Rule429InitlFctvDt>
    <ffd:Rule429SctyTp contextRef="prosp_2" id="ixv-444">Equity</ffd:Rule429SctyTp>
    <ffd:Rule429SctyTitl contextRef="prosp_2" id="ixv-445">Common Stock, par value $0.0001 per share</ffd:Rule429SctyTitl>
    <ffd:Rule429NbOfUnsoldScties
      contextRef="prosp_2"
      decimals="0"
      id="ixv-446"
      unitRef="Shares">6621190</ffd:Rule429NbOfUnsoldScties>
    <ffd:Rule429AggtOfferingAmt
      contextRef="prosp_2"
      decimals="2"
      id="ixv-447"
      unitRef="USD">0.00</ffd:Rule429AggtOfferingAmt>
    <ffd:Rule429EarlierFormTp contextRef="prosp_2" id="ixv-448">S-1</ffd:Rule429EarlierFormTp>
    <ffd:Rule429EarlierFileNb contextRef="prosp_2" id="ixv-449">333-290800</ffd:Rule429EarlierFileNb>
    <ffd:Rule429InitlFctvDt contextRef="prosp_2" id="ixv-450">2025-10-29</ffd:Rule429InitlFctvDt>
    <ffd:Rule429PrspctsNote contextRef="prosp_1" id="ixv-451">Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement (the "Registration Statement") covers an undetermined number of additional securities of Turn Therapeutics Inc. (the "Company") that may become issuable to prevent dilution from stock splits, stock dividends or similar transactions.

No registration fee is payable in connection with the shares of common stock that were previously registered on the Company's registration statement on Form S-1 (File No. 333-289972) (together with the exhibits thereto, "Prior Registration Statement I"), which was originally filed with the SEC on September 2, 2025 and declared effective by the SEC on September 30, 2025, and was amended by Post-Effective Amendment No. 1 thereto, which was declared effective by the SEC on April 2, 2026, because such shares are being transferred from Prior Registration Statement I to this Registration Statement pursuant to Rule 429 under the Securities Act. Pursuant to Rule 429(b) under the Securities Act, this Registration Statement, upon effectiveness, will constitute a post-effective amendment to Prior Registration Statement I, which post-effective amendment will become effective concurrently with the effectiveness of this Registration Statement in accordance with Section 8(c) of the Securities Act.

Represents 17,868,760 shares of common stock, all of which were originally registered for resale on Prior Registration Statement I.</ffd:Rule429PrspctsNote>
    <ffd:Rule429PrspctsNote contextRef="prosp_2" id="ixv-452">Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement (the "Registration Statement") covers an undetermined number of additional securities of Turn Therapeutics Inc. (the "Company") that may become issuable to prevent dilution from stock splits, stock dividends or similar transactions.

No registration fee is payable in connection with the share of common stock that were previously registered on the Company's registration statement on Form S-1 (File No. 333-290800) (together with the exhibits thereto, "Prior Registration Statement II" and, together with Prior Registration Statement I, the "Prior Registration Statements"), which was originally filed with the SEC on October 9, 2025 and became effective automatically on October 29, 2025 pursuant to Section 8(a) of the Securities Act, and was amended by Post-Effective Amendment No. 1 thereto, which was declared effective by the SEC on April 2, 2026, because such shares are being transferred from Prior Registration Statement II to this Registration Statement pursuant to Rule 429 under the Securities Act. Pursuant to Rule 429(b) under the Securities Act, this Registration Statement, upon effectiveness, will constitute a post-effective amendment to Prior Registration Statement II, which post-effective amendment will become effective concurrently with the effectiveness of this Registration Statement in accordance with Section 8(c) of the Securities Act.

Represents 6,621,190 shares of common stock, all of which were originally registered for resale on Prior Registration Statement II, consisting of (A) 1,597,959 shares of common stock currently held by GEM Global Yield LLC SCS and GEM Yield Bahamas Limited (together, "GEM"), comprising (1) 579,664 shares issued to GEM on August 13, 2026 upon the cashless exercise in full of a warrant to purchase 1,192,207 shares of common stock issued to GEM on October 8, 2025, (2) 161,905 shares issued to GEM on October 29, 2025 in payment of a commitment fee and (3) 856,390 of the 1,235,200 shares issued to GEM pursuant to the initial draw down notice under the amended and restated share purchase agreement, dated August 29, 2025, between the Company and GEM (as amended by a side letter dated as of September 24, 2025, the "GEM Purchase Agreement"), and (B) 5,023,231 shares of common stock issuable to GEM pursuant to the GEM Purchase Agreement.</ffd:Rule429PrspctsNote>
</xbrl>
